Cancer Society of New Zealand

Recent papers from Cancer Society of New Zealand

1. Minigene-based characterization and classification of splice-associated variants in succinate dehydrogenase Bnpj Precision Oncology · 2026
2. Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient‐Derived Glioma CellsChemMedChem · 2026
3. Succinate dehydrogenase germline mutation carriers: before tumours developEndocrine Related Cancer · 2026
4. Detection of Human Cytomegalovirus lncRNA4.9 in Breast Tumor Tissue Using RNA In Situ HybridizationJournal of Histochemistry & Cytochemistry · 2026
5. A cryptic allosteric pocket shapes isoform‐selective inhibition of human malic enzymesProtein Science · 2026
6. Discovery of a Novel Miconazole Analogue as a Dual Apo-Ido1 Inhibitor and Abcb1 Modulator for Cancer Immunotherapy and Chemosensitizing.2026
7. Cardiovascular Risk Following COPD Exacerbations in New Zealand: The Nationwide EXACOS-CV NZ StudyHeart Lung and Circulation · 2026
8. World Health Organization Healthy Ageing model applied to adults with cerebral palsy: A systematic review of reported intrinsic capacity measuresDevelopmental Medicine & Child Neurology · 2026
9. Equitable Reach, Engagement, and Mental Health Outcomes of a Digital Prostate Cancer Survivorship Program Across Rural and Urban Settings: Results from an International Phase 4 TrialJU Open Plus · 2026
10. Strategies for engineering biomimetic lipoproteins to improve drug delivery efficiency and tumor therapyDrug Delivery and Translational Research · 2026
11. A pH-sensitive nanococktail enabled cancer stem cell elimination, deep tumour penetration, and tumour shrinkageInternational Journal of Pharmaceutics · 2026
12. Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug DiscoveryMedicinal Research Reviews · 2026
13. Harnessing Targeted Protein Degradation for Developing Brain Cancer TherapyBioconjugate Chemistry · 2026
14. Evaluating Oxaliplatin Exposure in Adults with Advanced Colorectal Cancer: Development and Validation of Methods with Enhanced Bioanalytical Specificity and Clinical Applicability.2026
15. BIRC5 Promoter-Driven Nanodrugs Suppress BIRC5-Positive Cancers Independent of ABCB1 Status and IDO1 ExpressionInternational Journal of Nanomedicine · 2026
16. In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of GlioblastomaChemMedChem · 2026
17. Assessment of Antimicrobial Resistance in M. leprae Strains From KiribatiTropical Medicine & International Health · 2026
18. Clinical and genetic characteristics of head and neck paragangliomas from China featuring Sino-European comparisonsJournal of the Endocrine Society · 2026
19. Evaluating Sequencing Strategies for Endometrial Microbiome Profiling in Endometrial Cancer: A Comparative Study of Short‐ and Long‐Read 16S rRNA ApproachesCancer Reports · 2026
20. DJ-1 inhibition reshapes tumor microenvironment and potentiates immune checkpoint inhibitorsScience Advances · 2026